Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
1999 8
2000 60
2001 47
2002 54
2003 63
2004 69
2005 85
2006 72
2007 89
2008 130
2009 142
2010 152
2011 191
2012 229
2013 202
2014 253
2015 245
2016 262
2017 238
2018 232
2019 114
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

2,544 results
Results by year
Filters applied: . Clear all
Page 1
Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis.
Lucchetta RC, et al. CNS Drugs 2018 - Review. PMID 30014314
BACKGROUND: A broad range of disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) is available. ...
BACKGROUND: A broad range of disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS …
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
Brown JWL, et al. JAMA 2019 - Clinical Trial. PMID 30644981 Free PMC article.
IMPORTANCE: Within 2 decades of onset, 80% of untreated patients with relapsing-remitting multiple sclerosis (MS) convert to a phase of irreversible disability accrual termed secondary progressive MS. ...DESIGN, SETTING, AND PARTICIPANTS: Cohort study with prospective data from 68 neurology centers in 21 countries examining patients with relapsing-remitting MS commencing DMTs (or clinical monitoring) between 1988-2012 with minimum 4 years' follow-up. ...
IMPORTANCE: Within 2 decades of onset, 80% of untreated patients with relapsing-remitting multiple sclerosis (MS …
Ozanimod for the treatment of relapsing remitting multiple sclerosis.
Rasche L and Paul F. Expert Opin Pharmacother 2018. PMID 30407868
Ozanimod is a selective sphingosine 1-phosphate receptor 1 and 5 modulator under development by Celgene, for the treatment of relapsing remitting multiple sclerosis. ...Areas covered: The authors evaluate the literature of ozanimod, using the PubMed database as well as repositories of the European Committee for Treatment and Research in Multiple Sclerosis and the American and European Academy of Neurology. ...
Ozanimod is a selective sphingosine 1-phosphate receptor 1 and 5 modulator under development by Celgene, for the treatment of relapsing
Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review.
Merkel B, et al. Autoimmun Rev 2017 - Review. PMID 28428119 Free article.
BACKGROUND: Immunotherapy initiated early after first presentation of relapsing-remitting multiple sclerosis is associated with improved long-term outcomes. ...While this monitoring approach is logical, the current lack of effective regenerative or remyelinating therapies behoves us to consider high-efficacy treatment strategies from disease onset (including induction therapy) in order to prevent irreversible disability. ...
BACKGROUND: Immunotherapy initiated early after first presentation of relapsing-remitting multiple sclerosis is …
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study.
Selmaj K, et al. Lancet Neurol 2013 - Clinical Trial. PMID 23764350
We aimed to determine the dose-response relation of siponimod in terms of its effects on brain MRI lesion activity and characterise safety and tolerability in patients with relapsing-remitting multiple sclerosis. METHODS: In this double-blind, adaptive dose-ranging phase 2 study, we enrolled adults (aged 18-55 years) with relapsing-remitting multiple sclerosis at 73 medical centres in Europe and North America. ...
We aimed to determine the dose-response relation of siponimod in terms of its effects on brain MRI lesion activity and characterise safety a …
Silent progression in disease activity-free relapsing multiple sclerosis.
University of California, San Francisco MS-EPIC Team , et al. Ann Neurol 2019. PMID 30851128 Free PMC article.
OBJECTIVE: Rates of worsening and evolution to secondary progressive multiple sclerosis (MS) may be substantially lower in actively treated patients compared to natural history studies from the pretreatment era. ...We propose the term silent progression to describe the insidious disability that accrues in many patients who satisfy traditional criteria for relapsing-remitting MS. ...
OBJECTIVE: Rates of worsening and evolution to secondary progressive multiple sclerosis (MS) may be substantially lower in act …
Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis.
Thomas K, et al. Expert Opin Pharmacother 2017 - Review. PMID 28844164
Growing evidence demonstrates additional effects beyond impact on lymphocyte circulation, highlighting further promising targets in multiple sclerosis therapy. ...Further studies are essential to discuss additional benefit in progressive forms in multiple sclerosis....
Growing evidence demonstrates additional effects beyond impact on lymphocyte circulation, highlighting further promising targets in multi
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
Gold R, et al. N Engl J Med 2012 - Clinical Trial. PMID 22992073 Free article.
METHODS: We conducted a randomized, double-blind, placebo-controlled phase 3 study involving patients with relapsing-remitting multiple sclerosis. ...CONCLUSIONS: In patients with relapsing-remitting multiple sclerosis, both BG-12 regimens, as compared with placebo, significantly reduced the proportion of patients who had a relapse, the annualized relapse rate, the rate of disability progression, and the number of lesions on MRI. ...
METHODS: We conducted a randomized, double-blind, placebo-controlled phase 3 study involving patients with relapsing-remitting
Evolving concepts in the treatment of relapsing multiple sclerosis.
Comi G, et al. Lancet 2017 - Review. PMID 27889192
In the past 20 years the treatment scenario of multiple sclerosis has radically changed. The increasing availability of effective disease-modifying therapies has shifted the aim of therapeutic interventions from a reduction in relapses and disability accrual, to the absence of any sign of clinical or MRI activity. The choice for therapy is increasingly complex and should be driven by an appropriate knowledge of the mechanisms of action of the different drugs and of their risk-benefit profile. ...
In the past 20 years the treatment scenario of multiple sclerosis has radically changed. The increasing availability of effect …
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
Tramacere I, et al. Cochrane Database Syst Rev 2015 - Review. PMID 26384035
BACKGROUND: Different therapeutic strategies are available for the treatment of people with relapsing-remitting multiple sclerosis (RRMS), including immunomodulators, immunosuppressants and biologics. ...SEARCH METHODS: We searched the Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group Trials Register, which contains trials from CENTRAL (2014, Issue 9), MEDLINE (1966 to 2014), EMBASE (1974 to 2014), CINAHL (1981 to 2014), LILACS (1982 to 2014), clinicaltrials.gov and the WHO trials registry, and US Food and Drug Administration (FDA) reports. ...
BACKGROUND: Different therapeutic strategies are available for the treatment of people with relapsing-remitting multiple
2,544 results
Jump to page
Feedback